RecruitingPriority 4 · Lower priorityNCT07132567
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Plain-language summary
This is a research study collecting clinical information and/or biological samples from patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease to advance understanding of these diseases and improve future treatments. No experimental treatment is given as part of this study. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 19 Years or older
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Poteligeo 20mg (DRUG): Poteligeo 20mg
Poteligeo 20mg
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details